Independent and Site-based Ratings of Symptom Severity in Pharmacogenetics Clinical Trials

Personalized medicine and pharmacogenomics hold strong promise for psychiatry. Studies in this area require novel approaches to ensure endpoint reliability and validity, reduce the impact of treatment unblinding, and minimize other confounds that reduce signal detection. At the American Psychiatric Association Annual Meeting, MedAvante-ProPhase presented analysis of a combination of novel assessment methods, including remote, independent ratings, to evaluate adherence to inclusion criteria and efficacy in pharmacogenetics clinical trials.

Download Poster